CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
CCRT followed by VIDL chemotherapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01007526
NCT01007526Phase 2Completed
CompareCT.gov

Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by VIDL Chemotherapy With Risk-based Application of Autologous Stem Cell Transplantation in Stage I/II Extranodal NK/T-cell Lymphoma

Samsung Medical Center·interventional·Posted Nov 4, 2009·Updated Feb 7, 2019

In Brief

A Phase 2 clinical trial evaluating CCRT followed by VIDL chemotherapy for NK/T-cell Lymphoma of Nasal Cavity. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This study is to evaluate the efficacy of risk-adapted treatment strategy for stage I/II extranodal NK/T cell lymphoma. The risk stratification is based on the Korean NK prognostic index. Thus, the group I/II will receive concomitant chemoradiation followed by VIDL chemotherapy. The group III/IV will receive high dose-chemotherapy followed by autologous stem cell transplantation after the completion of VIDL chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNK/T-cell Lymphoma of Nasal Cavity
CountriesSouth Korea
CollaboratorsAsan Medical Center, National Cancer Center, Korea, Severance Hospital

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 2009
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.7 years ago

Interventions

CCRT followed by VIDL chemotherapyother

CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation